• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立一种简单、快速、灵敏、高通量的基于荧光素酶报告基因的微量中和试验,用于测量呼吸道合胞病毒疫苗接种和感染后病毒中和抗体。

Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection.

机构信息

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Bethesda, MD 20892, USA.

出版信息

Vaccine. 2013 Aug 20;31(37):3987-94. doi: 10.1016/j.vaccine.2013.05.088. Epub 2013 Jun 4.

DOI:10.1016/j.vaccine.2013.05.088
PMID:23742994
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3779065/
Abstract

We have established a new reporter gene-based RSV neutralization test using Renilla luciferase. The RSV-Luciferase Neutralization Test (RSV-Luc-NeuT) is a simple, rapid, high throughput, and less labor intensive functional serological assay than the traditional RSV-PRNT, capable of measuring a broad range of anti-RSV neutralizing antibodies targeting both RSV-F and RSV-G proteins. Specificity and sensitivity of the RSV-Luc-NeuT are comparable to the RSV-PRNT. Panels of pre-vaccination and post-vaccination animal sera, monoclonal antibodies and animal polyclonal anti-RSV sera confirmed assay specificity. A panel of 60 human sera demonstrated high assay sensitivity for measurement of RSV neutralizing antibodies that strongly correlated with the RSV-PRNT titers (R(2)=0.864). Neutralization in the presence of guinea pig complement (GPC) increased PRNT titers more than the RSV-Luc-NeuT neutralizing antibody titers for these human sera. This newly developed simple, high throughput, RSV-Luc-NeuT could be easily automated and applied in measurement of RSV neutralization titers in large vaccine trials.

摘要

我们建立了一种新的基于荧光素酶的 RSV 中和试验,用于检测 RSV 中和抗体。与传统的 RSV-PRNT 相比,该方法具有简单、快速、高通量、劳动强度低等优点,能够检测针对 RSV-F 和 RSV-G 蛋白的广泛中和抗体。RSV-Luc-NeuT 的特异性和灵敏度与 RSV-PRNT 相当。预接种和接种后动物血清、单克隆抗体和动物多克隆抗 RSV 血清的面板证实了该检测方法的特异性。一组 60 个人类血清样本的检测结果表明,该方法对 RSV 中和抗体的检测具有较高的灵敏度,与 RSV-PRNT 滴度呈强相关性(R²=0.864)。在豚鼠补体(GPC)存在的情况下,中和作用使 PRNT 滴度增加的幅度大于 RSV-Luc-NeuT 中和抗体滴度。这种新开发的简单、高通量的 RSV-Luc-NeuT 可以很容易地自动化,并应用于大规模疫苗试验中 RSV 中和滴度的测量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/7257f7ed79fd/nihms506048f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/95d76f34ff63/nihms506048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/46522988b051/nihms506048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/dd0cb1a6af86/nihms506048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/a5f5ac512ba2/nihms506048f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/7257f7ed79fd/nihms506048f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/95d76f34ff63/nihms506048f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/46522988b051/nihms506048f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/dd0cb1a6af86/nihms506048f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/a5f5ac512ba2/nihms506048f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7395/3779065/7257f7ed79fd/nihms506048f5.jpg

相似文献

1
Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection.建立一种简单、快速、灵敏、高通量的基于荧光素酶报告基因的微量中和试验,用于测量呼吸道合胞病毒疫苗接种和感染后病毒中和抗体。
Vaccine. 2013 Aug 20;31(37):3987-94. doi: 10.1016/j.vaccine.2013.05.088. Epub 2013 Jun 4.
2
Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.自然感染及用福尔马林灭活呼吸道合胞病毒(RSV)疫苗接种后表位特异性抗呼吸道合胞病毒(抗RSV)抗体反应的特征分析
J Virol. 2016 Jun 10;90(13):5965-5977. doi: 10.1128/JVI.00235-16. Print 2016 Jul 1.
3
Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus.快速、高通量且稳健的基于成像的呼吸道合胞病毒中和测定法的开发和验证。
J Immunol Methods. 2021 Jul;494:113054. doi: 10.1016/j.jim.2021.113054. Epub 2021 Apr 15.
4
Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.微融合抑制试验:定量检测抗体中和病毒介导的细胞间融合。
J Gen Virol. 2021 Jan;102(1). doi: 10.1099/jgv.0.001506. Epub 2020 Oct 15.
5
Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.母体抗体增强呼吸道合胞病毒感染并不能解释婴儿疾病的严重程度。
J Virol. 2017 Oct 13;91(21). doi: 10.1128/JVI.00851-17. Print 2017 Nov 1.
6
Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.基于高通量呼吸道合胞病毒荧光灶的微量中和试验的开发
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00225-17. Print 2017 Dec.
7
Development and application of a higher throughput RSV plaque assay by immunofluorescent imaging.通过免疫荧光成像技术开发和应用更高通量 RSV 噬斑检测法。
J Virol Methods. 2019 Jan;263:88-95. doi: 10.1016/j.jviromet.2018.10.022. Epub 2018 Oct 28.
8
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.接种灭活呼吸道合胞病毒疫苗的婴幼儿血清中和抗体与糖蛋白抗体反应之间的解离
J Clin Microbiol. 1986 Aug;24(2):197-202. doi: 10.1128/jcm.24.2.197-202.1986.
9
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.呼吸道合胞病毒融合纳米颗粒疫苗免疫应答针对多个中和表位,有助于预防野生型和帕利珠单抗耐药突变病毒的挑战。
Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30.
10
Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.针对呼吸道合胞病毒融合蛋白的抗原表位特异性竞争抗体反应与造血细胞移植成人的病毒清除有关。
Front Immunol. 2019 Mar 29;10:706. doi: 10.3389/fimmu.2019.00706. eCollection 2019.

引用本文的文献

1
A Rapid Yeast-Based System for Modifying Respiratory Syncytial Virus.一种用于改造呼吸道合胞病毒的基于酵母的快速系统。
Methods Mol Biol. 2025;2948:59-71. doi: 10.1007/978-1-0716-4666-3_4.
2
Coumarins and Hesperetin Inhibit Human Respiratory Syncytial Virus Infection.香豆素和橙皮素抑制人呼吸道合胞病毒感染。
Int J Mol Sci. 2024 Dec 11;25(24):13301. doi: 10.3390/ijms252413301.
3
Virus neutralization assays for human respiratory syncytial virus using airway organoids.用人呼吸道合胞病毒气道类器官进行病毒中和测定。
Cell Mol Life Sci. 2024 Jun 17;81(1):267. doi: 10.1007/s00018-024-05307-y.
4
Monoclonal antibodies targeting sites in respiratory syncytial virus attachment G protein provide protection against RSV-A and RSV-B in mice.针对呼吸道合胞病毒附着 G 蛋白中位点的单克隆抗体为小鼠提供了针对 RSV-A 和 RSV-B 的保护。
Nat Commun. 2024 Apr 4;15(1):2900. doi: 10.1038/s41467-024-47146-2.
5
Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study.鼻内接种 5 型副流感病毒(PIV5)载体呼吸道合胞病毒(RSV)疫苗在一项 1 期临床研究中,在健康成年人中是安全且具有免疫原性的。
Sci Adv. 2023 Oct 27;9(43):eadj7611. doi: 10.1126/sciadv.adj7611. Epub 2023 Oct 25.
6
The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein.为老年人研发呼吸道合胞病毒疫苗的探索:超越融合蛋白的思考
Vaccines (Basel). 2023 Feb 7;11(2):382. doi: 10.3390/vaccines11020382.
7
Neosuberitenone, a New Sesterterpenoid Carbon Skeleton; New Suberitenones; and Bioactivity against Respiratory Syncytial Virus, from the Antarctic Sponge sp.Neosuberitenone,一种新型甾体碳骨架;新型穗醇;抗呼吸道合胞病毒的生物活性,来自南极海绵 sp.
Mar Drugs. 2023 Feb 1;21(2):107. doi: 10.3390/md21020107.
8
Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.基于结构的呼吸道合胞病毒 G 免疫原设计与抗原性验证。
J Virol. 2022 Apr 13;96(7):e0220121. doi: 10.1128/jvi.02201-21. Epub 2022 Mar 10.
9
Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain.在呼吸道合胞病毒融合蛋白中鉴定出的保护性抗原位点揭示了 p27 结构域的重要性。
EMBO Mol Med. 2022 Jan 11;14(1):e13847. doi: 10.15252/emmm.202013847. Epub 2021 Nov 8.
10
A Novel Live Attenuated Respiratory Syncytial Virus Vaccine Candidate with Mutations in the L Protein SAM Binding Site and the G Protein Cleavage Site Is Protective in Cotton Rats and a Rhesus Macaque.一种新型活减毒呼吸道合胞病毒疫苗候选株,其 L 蛋白 SAM 结合位点和 G 蛋白切割位点发生突变,在棉鼠和恒河猴中具有保护作用。
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01568-20.

本文引用的文献

1
Respiratory syncytial virus: current progress in vaccine development.呼吸道合胞病毒:疫苗研发的最新进展。
Viruses. 2013 Feb 5;5(2):577-94. doi: 10.3390/v5020577.
2
An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting.一种基于绿色荧光蛋白表达检测和自动噬斑计数的改良呼吸道合胞病毒中和测定法。
Virol J. 2012 Oct 31;9:253. doi: 10.1186/1743-422X-9-253.
3
Current progress on development of respiratory syncytial virus vaccine.呼吸道合胞病毒疫苗研发的最新进展。
BMB Rep. 2011 Apr;44(4):232-7. doi: 10.5483/BMBRep.2011.44.4.232.
4
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.针对大流行 H5N1 流感病毒的细菌 HA1 疫苗:在雪貂中具有寡聚化、血凝和交叉保护免疫的证据。
J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.
5
A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.基于流式细胞术的 RSV 特异性中和抗体检测方法具有可重复性、高效性和准确性。
J Immunol Methods. 2010 Oct 31;362(1-2):180-4. doi: 10.1016/j.jim.2010.08.005. Epub 2010 Aug 19.
6
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.全球儿童因呼吸道合胞病毒导致的急性下呼吸道感染负担:系统评价和荟萃分析。
Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.
7
Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on glycosaminoglycans.在非洲绿猴肾细胞(Vero细胞)中培养的呼吸道合胞病毒含有一种截短的附着蛋白,这种蛋白会改变其感染性以及对糖胺聚糖的依赖性。
J Virol. 2009 Oct;83(20):10710-8. doi: 10.1128/JVI.00986-09. Epub 2009 Aug 5.
8
Immunoprophylaxis and immunotherapy: role in the prevention and treatment of repiratory syncytial virus.免疫预防和免疫治疗:在预防和治疗呼吸道合胞病毒中的作用。
Int J Antimicrob Agents. 1993 Feb;2(2):97-103. doi: 10.1016/0924-8579(93)90047-9.
9
Replacement of the respiratory syncytial virus nonstructural proteins NS1 and NS2 by the V protein of parainfluenza virus 5.用副流感病毒5型的V蛋白替代呼吸道合胞病毒的非结构蛋白NS1和NS2。
Virology. 2007 Nov 10;368(1):73-82. doi: 10.1016/j.virol.2007.06.017. Epub 2007 Jul 16.
10
Respiratory syncytial virus infection in elderly and high-risk adults.老年人及高危成年人的呼吸道合胞病毒感染
N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951.